Basics Altimmune, Inc. Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. IPO Date: May 22, 2017 Sector: Healthcare Industry: Biotech Market Cap: $333.61M Activated in VL: True Average Daily Range Avg Daily Range: $0.31 | 4.14% Avg Daily Range (30 D): $0.09 | 2.41% Avg Daily Range (90 D): $0.16 | 3.40% Institutional Daily Volume Avg Daily Volume: 1.83M Avg Daily Volume (30 D): 2.63M Avg Daily Volume (90 D): 4.35M Trade Size Avg Trade Size (Sh.): 159 Avg Trade Size (Sh.) (30 D): 202 Avg Trade Size (Sh.) (90 D): 182 Institutional Trades Total Inst.Trades: 1,453 Avg Inst. Trade: $1.72M Avg Inst. Trade (30 D): $.64M Avg Inst. Trade (90 D): $1.23M Avg Inst. Trade Volume: .19M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.97M Avg Closing Trade (30 D): $.64M Avg Closing Trade (90 D): $1.2M Avg Closing Volume: 222.77K     News Sep 7, 2025 @ 4:10 PM Bragar Eagel & Squire, P.C. Reminds Investors of N... Source: Bragar Eagel & Squire, P.C. Sep 7, 2025 @ 1:06 PM Faruqi & Faruqi Reminds Altimmune Investors of the... Source: Faruqi & Faruqi, Llp Sep 5, 2025 @ 8:56 PM Lost Money on Altimmune, Inc. (ALT)? Join Class Ac... Source: Levi & Korsinsky, Llp Sep 5, 2025 @ 6:23 PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimm... Source: Rosen Law Firm Sep 3, 2025 @ 8:00 PM ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman ... Source: Bronstein, Gewirtz & Grossman Llc Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.27 $-.26 $-.32 Diluted EPS $-.27 $-.26 $-.32 Revenue $ .01M $ .01M $ .01M Gross Profit $ $ $ Net Income / Loss $ -22.15M $ -19.58M $ -22.85M Operating Income / Loss $ -22.92M $ -21.82M $ -24.77M Cost of Revenue $ $ $ Net Cash Flow $ 134M $ 12.18M $ -25.65M PE Ratio     Splits Sep 14, 2018:   1:30 May 05, 2017:   1:10 May 04, 2017:   1:10 Jul 25, 2007:   1:50